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Population samples: Discovery 
Cooperative Health Research in the Region of Augsburg (KORA) 
 KORA (Cooperative Health Research in the Region of Augsburg) is a research platform 
of independent population-based health surveys and subsequent follow-up examinations 
of individuals of German nationality resident in the region of Augsburg in Southern 
Germany. Written informed consent was obtained from all participants and the studies 
have been approved by the ethics committee of the Bavarian Medical Association. Study 
design, sampling method and data collection have been described in detail elsewhere.1 
The surveys S3 and S4 were conducted in 1994/1995 and 1999-2001, respectively, and 
comprised independent samples of 4856 and 4261 subjects aged 25 to 74 years. Both 
cohorts were reinvestigated in the follow-up examinations F3 and F4 in 2004/2005 and 
2006-2008, respectively, with 2974 and 3080 participants. Anthropometric variables and 
clinical parameters were determined at all examinations. 
 For the primary analysis of the present study, DNA methylation measurements from a 
representative subsample of 1709 KORA F4 participants were considered, as well as from 
a sample of 485 smokers and never smokers from the KORA F3 examination.2 For the 
longitudinal analysis, measurements from 1435 KORA S4 participants were also included. 
For the incident T2D analysis, measurements from a nested case-control study within 
KORA S3/S4 was used, comprising 200 subjects with newly diagnosed T2D (S3: physician 
diagnosis, S4: physician diagnosis validated through OGTT) and 200 controls matched for 
age (±2 years), sex, cohort and observation time until diagnosis of diabetes. DNA 
methylation was measured with the Infinium HumanMethylation450K BeadChip® (Illumina, 
Inc., CA, USA). Sample preparation and measurement have been described in detail 
elsewhere.2 
The London Life Sciences Prospective Population Study (LOLIPOP) 
 LOLIPOP is a prospective cohort study of ~28K Indian Asian and European men and 
women, recruited from the lists of 58 General Practitioners in West London, United 
Kingdom between 2003 and 2008.3 At enrolment all participants completed a structured 
assessment of cardiovascular and metabolic health, including anthropometry, and 
collection of blood samples for measurement of fasting glucose, insulin and lipid profile, 
HbA1c, and complete blood count with differential white cell count. Aliquots of whole blood 
were stored at -80C for extraction of genomic DNA. DNA methylation measurement was 
performed amongst 2,680 participants of the LOLIPOP study free from T2D (physician 
diagnosis or HbA1c≥6.5%), using genomic DNA from peripheral blood collected at 
enrolment.4 The LOLIPOP study is approved by the National Research Ethics Service 
(07/H0712/150) and all participants gave written informed consent. 
 
Italian cardiovascular component of the European Prospective Investigation into Cancer 
and Nutrition (EPICOR) 
 EPICOR is a nested case-cohort study within the EPIC-Italy cohort of ~50,000 
participants recruited between 1994-1998.5,6 The enrolment assessment included a 
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detailed dietary and lifestyle questionnaire, as well as collection of a non-fasting peripheral 
blood sample. The cohort is under long-term follow-up for incident disease including 
cancers and other non-communicable disorders. The Whole genome DNA methylation 
was measured in genomic DNA from peripheral blood collected at enrolment in 292 
EPICOR participants who experienced non-fatal myocardial infarction during follow-up, 
and 292 healthy controls matched for age and gender. All participants are of European 
ancestry.  
 
Population samples: Replication  
Avon Longitudinal Study of Parents and Children (ALSPAC) 
 ALSPAC is a large, prospective cohort study based in the South West of England. 
14,541 pregnant women resident in Avon, UK with expected dates of delivery 1st April 
1991 to 31st December 1992 were recruited and detailed information has been collected 
on these women and their offspring at regular intervals.7,8 The study website contains 
details of all the data that is available through a fully searchable data dictionary 
(http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/). Written informed 
consent has been obtained for all ALSPAC participants. Ethical approval for the study was 
obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics 
Committees. 
 As part of the ARIES (Accessible Resource for Integrated Epigenomic Studies, 
http://www.ariesepigenomics.org.uk/) project, the Infinium HM450 BeadChip was used to 
quantify DNA methylation in genomic DNA from peripheral blood amongst 1,018 mother-
offspring pairs from the ALSPAC cohort. The ARIES participants were selected based on 
availability of DNA samples at two time points for the mother (antenatal and at follow-up 
when the offspring were adolescents). Methylation samples from the latter time point are 
included in this analysis. The DNA methylation wet-lab and pre-processing analyses were 
performed at the University of Bristol.  
 
Biobank-based Integrative Omics Studies (BIOS) Consortium 
 The mission of the BIOS Consortium is to create a large-scale data infrastructure and to 
bring together researchers focusing on integrative omics studies in Dutch Biobanks. The 
BIOS Consortium applies a functional genomics approach that integrates genome-wide 
genetic data with data on the epigenome and transcriptome to elucidate these 
mechanisms. Over BIOS consortium includes ~4000 samples from the Leiden Longevity 
Study, the LIFELINES Deep study and the Rotterdam study (RS-BIOS).  
 The Leiden Longevity Study (http://www.molepi.nl) consists of offspring of nonagenarian 
sibling pairs aged >90 years, and the partners of these offspring as population controls. 
LifeLines (http://www.lifelines.nl) is a population based study of 165,000 participants from 
the northern provinces of the Netherlands aimed at investigating the relationship between 
biomarkers and healthy ageing. The Rotterdam Study is a large prospective, population 
based cohort study in the district of Rotterdam, the Netherlands, investigating the 
prevalence, incidence, and risk factors of various chronic disabling diseases among eldery 
Caucasians aged 45 years and over. 
 
Estonian Genome Centre University of Tartu (EGCUT) study. 
 EGCUT is a population based biobank of 51,530 individuals age≥18 years in Estonia.9 
All participants completed a computer assisted interview, including personal data (place of 
birth, place(s) of living, nationality etc.), genealogical data (family history, three 
generations), educational and occupational history and lifestyle data (physical activity, 
dietary habits, smoking, alcohol consumption, quality of life). Anthropometric and 
physiological measurements were also recorded. The samples used in this study were 
selected from the EGCUT Center for Translational Genomics (CTG) cohort of individuals 
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who have been re-contacted for a second time-point sample (N=96), and the EGCUT 
asthma cohort (N=173) a set of non-obese, non-smoking individuals with early onset 
asthma, and matched controls. The collection of blood samples and data generation are 
conducted according to the Estonian Human Gene Research Act and all participants have 
signed a broad informed consent.  
 
The LOLIPOP Study 
 LOLIPOP has been described above. A further 656 Indian Asian samples 
representative of the LOLIPOP participants were available for replication testing. DNA 
methylation was quantified in genomic DNA from peripheral blood.  
 
The Rotterdam Study (RS)  
RS is a large prospective population-based cohort study including men and women of 
45 years and over. The design and rationale of this study are described in detail 
elsewhere.10 In summary, the Rotterdam Study aims to investigate the determinants, 
incidence and progression of chronic disabling diseases in the elderly. The first cohort, 
Rotterdam Study I (RS-I) was initiated in 1989 including 7983 persons aged 55 years and 
older and was extended in 1999 with 3011 participants in Rotterdam Study II (RS-II). In 
2005, Rotterdam Study III (RS-III) added another 3932 individuals aged 45 years and 
older. All participants were examined in detail at baseline and follow-up visits every ±5 
years. In summary, a home interview was conducted and the subjects underwent an 
extensive set of examinations at the research center, including cardiovascular and 
metabolic health. DNA was isolated from whole blood using standard procedures. 
Epigenome-wide methylation scans were carried out on the DNA collected at the baseline 
visit of the RS-III cohort (the RS-III dataset), or at the fifth follow-up measurement in all 
three Rotterdam cohorts (RS-BIOS dataset).  
TwinsUK cohort (TwinsUK) 
 Epigenome wide association scans were performed in 355 whole blood samples and in 
542 adipose tissue biopsy samples from TwinsUK subjects. The TwinsUK cohort is a 
nationwide registry of healthy volunteer twins in the United Kingdom, with about 13,000 
registered twins since 1992, with predominately Caucasian female (84%) and equal 
number of monozygotic and dizygotic twins. Participants completed phenotype 
questionnaires, including information about their health, self and family disease history, 
medication use, and habitual behaviours, such as smoking and alcohol consumption.  The 
data include collections of clinical, phenotype, and biochemical measures from biological 
samples often profiles at multiple time points. DNA methylation profiles were generated 
using the Illumina 450k array in both blood and adipose tissue samples. The subjects 
included in the methylation analyses were free from severe diseases, such as cancer. 
Whole blood aliquots were stored at -80C and DNA was extracted using standard 
protocols. Adipose tissue biopsies and DNA methylation profiling were performed as 
previously described.11 
 
LifeLines Deep 
 Epigenome wide association was done amongst 752 participants of the LifeLines 
Cohort Study (Supplementary Table 1). The LifeLines Cohort Study is a large population-
based cohort study and biobank that was established as a resource for research on 
complex interactions between environmental, phenotypic and genomic factors in the 
development of chronic diseases and healthy ageing. Between 2006 and 2013, inhabitants 
of the northern part of The Netherlands and their families were invited to participate, 
thereby contributing to a three-generation design. Participants visited one of the LifeLines 
research sites for a physical examination, including lung function, ECG and cognition tests, 
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and completed extensive questionnaires. Baseline data were collected for 167 729 
participants, aged from 6 months to 93 years.12 At enrolment all participants completed a 
structured assessment of cardiovascular and metabolic health, including anthropometry, 
and collection of blood samples for measurement of fasting glucose, insulin and lipid 
profile, HbA1c, and complete blood count with differential white cell count. Aliquots of 
whole blood were stored at -80C for extraction of genomic DNA. Epigenome-wide 
methylation scans were carried out on the DNA collected at enrolment to the LifeLines 
study. 
 
Leiden Longevity Study (Leiden Longevity) 
 Epigenome wide association was done amongst 642 participants of the Leiden 
Longevity Study (LLS) (Supplementary Table 1). LLS consists of offspring of nonagenarian 
sibling pairs of which the members are aged over 90 years. The partners of these offspring 
were recruited as population controls. The study has been designed to investigate 
biomarkers of healthy ageing and longevity.13 Samples for methylation analysis were 
unrelated individuals selected from the partner and offspring groups. 
 
Replication testing in liver 
 The collection and analysis of liver samples has been described previously.14 In brief, 
liver samples were obtained percutaneously for patients undergoing liver biopsy for 
suspected NAFLD or intraoperatively for assessment of liver histology. Normal control 
samples were recruited from samples obtained for exclusion of liver malignancy during 
major oncological surgery. None of the normal control individuals underwent pre-operative 
chemotherapy and liver histology demonstrated absence of both cirrhosis and malignancy, 
For methylation analysis, bisulfite conversion was performed using the Zymo EZ DNA 
Methylation Kit (Zymo Research, Orange, CA, USA), and hybridization of the Illumina 
HumanMethylation450 array (Illumina, SanDiego, CA) according to the manufacturers 
protocols. Hybridization signals were analyzed using GenomeStudio software (default 
settings; GenomeStudio ver. 2011.1, Methylation Analysis Module ver. 1.9.0; Illumina Inc) 
and internal controls for normalization. 
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Supplementary Tables 
 
Supplementary Information Table 1. Characteristics of cohorts and participants. Results 
are presented as mean (SD) for continuous and % for categoric variables. 
 
Supplementary Information Table 2. Cohort-specific methodological details for 
quantification and analysis of DNA methylation. PC: principal component; QN: quantile 
normalization; WBC: white blood cell; SWAN: subset-quantile within array normalization. 
 
Supplementary Information Table 3. Results for the 278 CpG sites markers reaching 
P<1x10-7 in the epigenome-wide association study of the relationship between DNA 
methylation in blood and BMI. Results are presented for the discovery and replication 
phases, and in combined analysis. DNA methylation is quantified on a scale of 0-1, where 
1 represents 100% methylation. Sentinel marker: identifies the marker with the lowest P 
value at each locus. Replicate: indicates that the marker reaches P<0.05 with consistent 
direction of effect in replication testing. Mean (SD) methylation: is average methylation 
(standard deviation) at the CpG site in blood. Effect (SE): is change in BMI (kg/m2) per unit 
increase in methylation (ie from 0 to 1) from linear regression, and its standard error. The 
sentinel marker for each locus is indicated. Phet EUR/SA: P value for assessment of 
heterogeneity of effect between Europeans (Eur) and Indian Asians (IA). Phet: P value for 
assessment of heterogeneity of effect between the contributing cohorts.  N: sample size. 
The ‘Comments’ column annotates probes that have SNPs in probe sequence, or are 
reported to potentially cross-hybridise. 
 
Supplementary Information Table 4. Cohort specific results for the 207 sentinel CpG 
sites carried forward from the discovery phase into replication testing. DNA methylation is 
quantified on a scale of 0-1, where 1 represents 100% methylation. Mean (SD) 
methylation: is mean and standard deviation for methylation at the CpG site in blood. 
Effect (SE): is change in BMI (kg/m2) per unit increase in methylation (ie from 0 to 1) from 
linear regression, and its standard error. N: sample size. P: cohort specific P value for 
association of BMI with methylation. 
 
Supplementary Information Table 5. Association between methylation in blood and BMI 
at CpGs with SNPs in probe sequence. Results are shown for the association of CpG with 
BMI before and after adjustment for genotype of the SNP in the probe sequence (PCpG vs 
BMI and PCpG vs BMI adjusted respectively). In addition the association of the SNP under the 
probe with BMI and with methylation of the CpG are provided (PSNP vs BMI and PSNP vs CpG 
respectively). There is no evidence for genetic confounding by SNPs located in Infinium 
450k probe sequences. 
 
Supplementary Information Table 6. Association of DNA methylation in blood with BMI 
at 4 representative CpG sites assayed by pyrosequencing in 990 European and 1,720 
Indian Asian participants of the LOLIPOP study, and in combined analysis of the data from 
the 2 ethnic groups. This was carried out as a technical validation experiment. Effect (SE): 
is change in BMI (kg/m2) per unit increase in methylation (ie from 0 to 1) from linear 
regression, and its standard error. P: is the P value for association between BMI and 
methylation, from linear regression. Results confirm the association of methylation with 
BMI at these 4 loci using an alternate method for quantification of methylation.  
 
Supplementary Information Table 7. Characteristics of the 30 obese cases and 30 
normal weight controls participating in the study of DNA methylation in isolated white cell 
subsets. Results are presented as mean (SD) for continuous and % for categoric 
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variables. P values are for the comparison between obese cases and normal weight 
controls. 
 
Supplementary Information Table 8. Association of obesity with DNA methylation at the 
179 sentinel CpG sites assayed in isolated white cell subsets. Results are provided for 
sentinel markers in whole blood (from the discovery epigenome-wide association study), 
and for the 4 isolated white cell subsets (monocytes, neutrophils, CD4+ and CD8+). Mean 
(SD) methylation: is mean and standard deviation for methylation at the CpG site. 
Direction: the direction for association between methylation and BMI in the epigenome-
wide association of whole blood. PBMI: P value for association between methylation and 
BMI in epigenome-wide association of whole blood. Difference: the difference in 
methylation between obese cases and normal weight controls in the respective white cell 
subset, ([case]-[control], quantified on a scale of 0-1, where 1 represents 100% 
methylation). Pobesity: P value for association between methylation and obesity case-control 
status in the respective white cell subset. Consistent: directional consistency between the 
association of methylation with obesity in isolated white blood cells and the association of 
methylation with BMI in whole blood (‘+’ indicates a consistent direction of effect, ‘-‘ 
indicates opposite direction of effect).  
 
Supplementary Information Table 9. Association of the sentinel methylation markers 
with adiposity in isolated white cell subsets from 30 obese cases and 30 normal weight 
controls. Results are available for 179 of the 187 sentinel markers and are presented as i. 
number of loci associated with obesity at nominal significance (P<0.05); ii. number of loci 
associated with obesity at P<2.8x10-4 (ie P<0.05 after Bonferroni correction for 179 tests), 
and iii. number of loci showing an association with obesity that is directionally consistent 
with the association of BMI with methylation in the discovery epigenome-wide experiment. 
Enrichment P: statistical test for enrichment in directional consistency (Binomial ‘sign’ test). 
 
Supplementary Information Table 10. DNA methylation in subcutaneous adipose tissue 
(N=543 samples), and separately in liver tissue (N=55 samples), at the 187 sentinel CpG 
sites. Mean and standard deviation (SD) methylation levels in adipose tissue are provided 
for the CpG sites; DNA methylation is quantified on a scale of 0-1, where 1 represents 
100% methylation. The association of methylation with BMI are provided separately for 
adipose and liver tissue: effect is change in BMI (kg/m2) per unit increase in methylation (ie 
from 0 to 1) from linear regression, and its standard error (SE); the column ‘consistent’ 
compares direction of effect for the association of methylation with BMI in adipose or liver 
tissue with blood (discovery phase). Adipose-blood correlation: correlation between 
methylation levels in adipose tissue and blood in paired samples (N=201). NA: not 
available. The relationships of methylation with BMI at the sentinel CpG sites in blood are 
shown for comparison (from discovery EWAS, Supplementary Information Table 3). 
 
Supplementary Information Table 11. DNA methylation in isolated adipocytes and 
association with adiposity. Mean and standard deviation (SD) methylation levels in isolated 
adipocytes are provided for blood and adipocytes (obese cases and normal weight 
controls). DNA methylation is quantified on a scale of 0-1, where 1 represents 100% 
methylation. Difference: the difference in methylation between obese cases and normal 
weight controls ([Obese cases]-[Normal weight controls]). Pcase-control is for the comparison 
of methylation in obese cases with normal weight controls. The 6 markers reaching 
P<2.7x10-4 (ie P<0.05 after Bonferroni correction for 187 tests) for association with obesity 
in adipocytes are highlighted. Association results for markers in blood (discovery phase; 
association with BMI from Supplementary Information Table 3) are provided for 
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comparison. Consistent: consistent direction of effect for association with adiposity in 
blood and isolated adipocytes. 
Supplementary Information Table 12. Causality analysis to investigate whether DNA 
methylation in blood plays a causal role underlying obesity. EffectSNP-CpG: is change in 
methylation per unit copy of effect allele (A2, from Supplementary Information Table 12), 
from linear regression. SESNP-CpG: standard error of the effect. PSNP-CpG: is for the 
association of SNP with methylation. PSNP-CpG (adj): is for the association of SNP with 
methylation after Bonferroni correction for the number of SNPs in cis (within 1MB). 
EffectCpG-BMI: is change in BMI per unit increase in methylation (0-1 scale where 1 
represent 100%, from discovery epigenome-wide association study [Supplementary 
Information Table 3]). SECpG-BMI: standard error for the association of methylation on BMI. 
PCpG-BMI: is P value for the association of methylation with BMI. 
Predicted effect of SNP on BMI via methylation calculated from the product of SNP-CpG  
and CpG-BMI. Observed effect of SNP on BMI is from the GIANT study. The single locus 
(NFATC21P) where the observed effect of SNP on BMI reaches P<2.7x10-4 (ie P<0.05 
after Bonferroni correction for 187 tests) is highlighted in bold.  
 
Supplementary Information Table 13. Association of methylation in blood and BMI in 
cross-sectional and longitudinal studies as described below. In all analyses DNA 
methylation is quantified on a scale of 0-1, where 1 represents 100% methylation. 
‘Concordant direction’ is in relation to cross-sectional results from the discovery EWAS.  
 Cross-sectional (BMI-Meth) analysis: association of methylation with BMI in the 
discovery epigenome-wide association study (from Supplementary Information Table 
3). Effect (SE)Meth-BMI: is change in BMI (kg/m2) per unit increase in methylation (ie from 
0 to 1) and its standard error, from linear regression.  
 Longitudinal (Meth-ΔBMI) analysis: association of methylation at baseline with 
subsequent change in BMI during follow-up, amongst 1,435 Europeans and 1,513 
Indian Asians. Effect (SE)Meth-ΔBMI: is longitudinal change in BMI (kg/m2) between 
baseline and follow-up, per unit increase in methylation (ie from 0 to 1) at baseline, and 
its standard error, from linear regression.  
 Longitudinal (ΔMeth-ΔBMI) analysis: association of change in methylation between 
baseline and follow-up with change in BMI between baseline and follow-up amongst 
1,435 Europeans. Effect (SE)ΔMeth-ΔBMI: is longitudinal change in BMI (kg/m2) between 
baseline and follow-up, per unit increase in methylation (ie from 0 to 1) between 
baseline and follow-up, and its standard error, from linear regression. 
Results show that the change in BMI associated with change in methylation during follow-
up is closely correlated with the cross-sectional relationship of BMI with methylation 
(r=0.81, P<0.001)  
 
Supplementary Information Table 14. Causality analysis to investigate whether DNA 
methylation in blood is the consequence of obesity. GRS: Genetic Risk Score comprising 
sum of risk alleles for SNPs associated with BMI in the GIANT study, weighted by the per 
allele effect size of SNP on BMI. To make results comparable to the GIANT study, BMI is 
inverse normalised for this specific analysis. The association of GRS with BMI (outcome 
variable) is provided as EffectGRS-BMI, the change in BMI (inverse normalised) per unit 
change in GRS, with standard error (SEGRS-BMI) and P value (PGRS-BMI). The association of 
BMI (inverse normalised) with methylation (outcome variable) is provided as EffectBMI-CpG, 
the change in methylation (0-1 scale where 1 represent 100%) per unit change in BMI 
(inverse normalised), along with standard error (SEBMI-CpG) and P value (PBMI-CpG). 
Predicted effects of GRS on methylation via BMI calculated from the product of GRS-BMI 
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and BMI-CpG associations. Observed effect of GRS on methylation (outcome variable) 
directly quantified amongst participants of LOLIPOP and KORA studies as described in 
Online Methods. The three loci where Observed effect of GRS on methylation reaches 
P<2.7x10-4 (ie P<0.05 after Bonferroni correction for 187 tests) are highlighted in bold. 
  
Supplementary Information Table 15. Characteristics of individuals included in the gene 
expression studies. 
 
Supplementary Information Table 16. Association of gene expression with DNA 
methylation in blood. Results are presented for all genes identified to have expression 
QTLs associated with DNA methylation at P<0.05 after correction for multiple testing 
(N=5,551 tests), within 500kb of the 187 sentinel CpG sites. Distance: genomic distance 
between CpG and expressed gene. Mean (SD) expression: is for mean level of transcript 
in the samples. EffectCpG-Tx and SECpG-Tx: change in log2-transformed gene expression 
level per unit change (0 to 100%) in methylation, and standard error, from linear 
regression. PCpG-Tx: is P value for association of methylation with transcript in respective 
population sample or in meta-analysis. Phet: P value for assessment of heterogeneity of 
effect between the contributing cohorts. Association of gene expression with BMI in blood 
is also provided for comparison, where EffectBMI-Tx and SEBMI-Tx are: change in log2-
transformed gene expression level per 1kg/m2 increase in methylation, and standard error, 
from linear regression 
 
Supplementary Information Table 17. Association of gene expression with DNA 
methylation in blood, for genes that are i. nearest, or ii. annotated by Illumina as the target 
gene, for the 187 sentinel CpG sites. Results are shown for genes reaching P<0.05 after 
Bonferroni correction for the number of CpG-transcript pairs tested (500kb gene: 
P<9.0x10-6; nearest gene: P<2.0x10-4; Illumina gene: P<2.2x10-4). The lower threshold 
required for statistical significance is lower in the 500kb interval approach as a result of the 
greater burden of multiple testing compared to ‘nearest’ or ‘Illumina’ strategies. Mean (SD) 
is for level of transcript. EffectCpG-Tx and SECpG-Tx: change in log2-transformed gene 
expression level per unit change (0 to 100%) in methylation, and standard error, from 
linear regression. PCpG-Tx: is P value for association of methylation with transcript. The 
column labelled ‘500kb gene?’ indicates whether the gene listed is identified under the 
primary strategy for assessment of the relationship between methylation and gene 
expression over a 500kb genomic interval. The columns labelled ‘Nearest gene?’ and 
‘Illumina gene?’ indicate whether the gene listed is nearest to the CpG, or annotated to the 
CpG site in the Illumina manifest, respectively. There are 6 genes identified as having an 
association of gene expression with methylation by the ‘nearest’ or ‘Illumina’ annotation 
strategy, which are not identified by the more conservative 500kb interval approach. 
 
Supplementary Information Table 18. Association of gene expression with DNA 
methylation in blood, subcutaneous adipose tissue and liver tissue. Results are shown for 
the 38 genes (column ‘Transcript gene’) which show an association of expression with 
DNA methylation in blood. Mean (SD) expression: is for mean level of transcript. EffectCpG-
Tx and SECpG-Tx: change in log2-transformed gene expression level per unit change (0 to 
100%) in methylation, and standard error, from linear regression. PCpG-Tx: is P value for 
association of methylation with transcript.  
 
Supplementary Information Table 19. Candidate genes at the 187 methylation loci 
associated with adiposity. Results are shown for i. nearest gene: gene nearest to the 
sentinel methylation marker; ii. Illumina gene: annotated by Illumina as the target gene; iii. 
eQTL of nearest gene (from Supplementary Information Table 20); iv. eQTL of Illumina 
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gene (from Supplementary Information Table 20); v. eQTL of any gene within 500kb of 
sentinel CpG site (from Supplementary Information Table 19). 
 
Supplementary Information Table 20. Pubmed summary for the candidate genes 
highlighted by the 187 sentinel methylation markers. 
 
Supplementary Information Table 21. Pathway analysis of candidate genes. Results are 
shown for the primary candidate gene criteria: i. gene nearest to CpG site, or ii. gene 
within 500kb and showing association between methylation and expression. Column 
names indicate data base origin and name of enriched pathways. P value: is enrichment P 
value based on permutation testing (10,000 sets of 187 matched CpGs, see Online 
Methods). FDR P value is P value corrected for multiple testing using the Benjamini-
Hochberg method (to control the false discovery rate [FDR] at 5 %). Rows correspond to 
genes belonging to the respective pathways. 
 
Supplementary Information Table 22. Association of DNA methylation in blood with 
metabolic traits linked to adiposity amongst participants of the LOLIPOP and KORA 
studies. Effect: change in the respective trait per unit increase in methylation (ie from 0 to 
1). DBP: diastolic blood pressure; Glc: fasting glucose; HDL: high density lipoprotein 
cholesterol, LDL: low density lipoprotein cholesterol; SBP: systolic blood pressure; TG: 
triglycerides; WHR: Waist-hip ratio. 
 
Supplementary Information Table 23. Association of methylation in blood at the 187 
sentinel CpG sites with incident type-2 diabetes (T2D). Results are provided for single 
marker tests (‘Single marker’) and in joint analysis of all 187 markers (‘Multi-marker’), 
with/without adjustment for BMI. Effect (SE): change in log odds for T2D per unit increase 
(ie 0 to 100%) in methylation and standard error, from logistic regression, with 
corresponding P value. 
 
Supplementary Information Table 24. DNA methylation in blood as a risk factor for 
future, incident Type-2 diabetes (T2D) amongst 2,664 Indian Asians (1,074 with incident 
T2D) and 400 Europeans (200 with incident T2D) and in meta-analysis. Results are 
presented as relative risk for T2D (with 95% confidence intervals [CI]) per 1SD increase in 
Methylation Risk Score. Results are shown before and after adjustment for adiposity and 
glycaemic measures as conventional risk factors for T2D. Phet is the P value for 
heterogeneity of effect between Indian Asians and Europeans. WHR: Waist-hip ratio.  
 
Supplementary Information Table 25. Cohort-specific methods for whole-genome 
genotyping and imputation of unmeasured genotypes for the Mendelian randomisation 
experiment, and for generation of principal components from whole-genome genotyping to 
quantify cryptic genetic population structure. MAF: minor allele frequency; HWE: Hardy-
Weinberg Equilibrium. 
 
Supplementary Information Table 26. Primers used for pyrosequencing in replication 
testing. 
Supplementary Information Table 27. All cis-SNPs (within 500kb) associated with 
methylation of the 187 sentinel CpG sites in blood at P<0.05. A1: is the alternate allele. 
A2: is the SNP effect allele. EAF: effect allele frequency (A2). EffectSNP-CpG: is change in 
methylation per unit copy of effect allele (A2), from linear regression. PSNP-CpG: is P value 
for the association of SNP with methylation. 
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Supplementary Information Table 28. Association of SNPs with DNA methylation in 
blood amongst Indian Asians and Europeans and in combined analysis. Results are 
shown for the single SNP with lowest P value for association with methylation at the 
sentinel CpG sites. A1: is the alternate allele. A2: is the SNP effect allele. EAF: effect allele 
frequency (A2). EffectSNP-CpG: is change in methylation per unit copy of effect allele (A2), 
from linear regression. SESNP-CpG: standard error of the effect. PSNP-CpG: is P value for the 
association of SNP with methylation in combined analysis. Phet: is the P value for 
heterogeneity of effect between the ethnic groups.  
 
Supplementary Information Table 29. Sensitivity analysis for the pathway analysis of 
candidate genes. Results are shown for the primary candidate gene criteria (nearest gene 
or gene expression association) and for alternate proximity selection criteria: i. Illumina: 
gene annotated by Illumina; ii. 10kb: all genes within 10kb of CpG site; iii. 20kb: all genes 
within 20kb of CpG site; iv. 40kb: all genes within 40kb of CpG site; v. 100kb: all genes 
within 100kb of CpG site. The 38 genes showing an association between methylation and 
expression in blood are included in all models. 
 
Supplementary Information Table 30. Published GWA studies used for investigation of 
causal relationships between 187 sentinel methylation markers and metabolic traits linked 
to adiposity.  
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Supplementary Figures 
 
 
Supplementary Information Figure 1. The accompanying pdf file provides 1Mb regional 
plots for the 187 sentinel CpG sites associated with BMI. Regional plots are ordered by 
chromosome and position and show 500kb either side of the sentinel marker. 
 
 
Supplementary Information Figure 2. The accompanying pdf file provides 20kb regional 
plots for the 187 sentinel CpG sites associated with BMI. Regional plots are ordered by 
chromosome and position and show 10kb either side of the sentinel marker. 
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Supplementary Information Figure 3. Scatterplot matrix of effect sizes (SF4A) and –log10(P) (SF4B), for association of methylation 
with BMI in blood derived from different models in a sensitivity analysis on the discovery epigenome-wide association study. Models 
evaluated are defined as follows: 20 CP PCs: original discovery model which includes 20 control probe PCs as covariates. 10 CP PCs, 
30 CP PCs, 40 CP PCs: models including 10, 30 and 40 control probe PCs. 10 Meth PCs, 20 Meth PCs: models including 10, 20 
methylation PCs in addition to the original discovery covariates. 10 Resid PCs, 20 Resid PCs: models including 10, 20 methylation PCs 
after adjusting methylation data for the discovery covariates and BMI, in addition to the original discovery covariates. 5 SNP PCs: models 
including 5 SNP PCs in addition to the original discovery covariates. 
 
  
ST3A: Effect size ST3B: -log10(P) 
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Supplementary Information Figure 4. Genetic confounding by SNPs located in Infinium 
450k probe sequences. Adjustment for the SNPs in probe sequence has no material 
impact on the P values for association in blood between methylation and BMI at the 
respective CpG sites. 
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Supplementary Information Figure 5. Mean methylation levels at the 187 sentinel CpG sites across 7 tissue types. Samples (rows, 
N=41) and CpG sites (columns, N=187) are ordered by hierarchical clustering of methylation levels with Euclidean distance as similarity 
measure. Methylation values range from 0 (red) to 1 (green). 
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Supplementary Information Figure 6. Sensitivity analysis on the association of methylation with BMI in adipose tissue. Comparison of 
effect sizes for association of the 187 sentinel CpG sites with BMI in blood (x-axis) and adipose tissue (y-axis), with / without correction 
for up to 20 adipose tissue methylation Principal Components. The P value is for directional consistency between blood and adipose 
tissue at the 187 sentinel CpG sites in each model (binomial test). 
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Supplementary Information Figure 7. Heatmap showing enrichment for DNase hypersensitivity sites (DHS) and histone marks at the 
187 sentinel CpG sites, across 127 cell lines from the Roadmap and ENCODE projects (compendium release 9). Red boxes: enriched at 
P<4x10-4 (ie P<0.05 after Bonferroni correction for 127 tests); Blue boxes: depleted at P<4x10-4 (ie P<0.05 after Bonferroni correction for 
127 tests); Grey boxes: no data. ESC: embryonic stem cell; IPSC: Induced Pluripotent stem cell; ES-deriv: embryonic stem cell derived; 
Mesench: Mesenchymal Stem cells; Neurosp: Neurospheres; ENCODE12: data from encode 2012 release. 
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Supplementary Information Figure 8. Heatmap showing the associations between 
methylation in blood at the 187 sentinel CpG sites and clinical traits relevant to adiposity. 
The associations are represented as signed -log10(P), values, with the sign corresponding 
to the direction of the beta regression coefficient. Dendrograms were constructed by 
complete linkage hierarchical clustering with Euclidean distance as similarity measure. 
Chol: total cholesterol; CRP: C-reactive protein; DBP: diastolic blood pressure; Glc: fasting 
glucose; HDL: high density lipoprotein cholesterol, LDL: low density lipoprotein cholesterol; 
SBP: systolic blood pressure; TG: triglycerides; WHR: Waist-hip ratio. 
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Supplementary Information Figure 9. Relationship between Principal Components 
(PCs) derived from methylation data in blood (methPC, x-axis) and genetic data (snpPC, 
y-axis) for LOLIPOP (Panel A) and the KORA (Panel B) cohorts. P-values are derived 
using linear regression and adjusted for the number of tests performed.  
 
 
 
 
 
 
 
  
A. LOLIPOP 
B. KORA 
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Supplementary Information Figure 10. Comparison of effects (beta-coefficients) and –
log10(P) for association of methylation in blood with BMI, with and without adjustment for 
genetic PCs 1-5. Linear regression was performed as described for the discovery 
epigenome-wide association study, but separately within each GWAS dataset followed by 
meta-analysis. Red dots represent the 187 significantly associated sentinel CpGs, grey 
points represent all other CpGs. 
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